| News

Versameb raises 6 million Swiss francs

17.07.2020

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Using revenues obtained from a seed financing round totaling 6 million Swiss francs, Versameb is planning to bring its VERSagile platform to the clinical development stage by the end of 2021, as detailed in a press release. Versameb has developed VERSagile in order to program mRNA sequences for improved therapeutic efficacy. To this end, a molecular algorithm developed by the Basel-based company is used. The molecules developed in this fashion are designed to be used in the areas of dermatology and oncology, as well in the field of myology, the study of muscle diseases.

The potential of the Versameb approach was recognized very early on by the investment and innovation promotion agency Basel Area Business & Innovation, which supported the company in 2017/18 by way of BaseLaunch, the organization’s biotech accelerator and incubator. Versameb has now set its sights on driving forward the development of the company. To this end, it has strengthened its management team with the addition of Klaas P. Zuideveld, who has been appointed Chief Development Officer (CDO). He will bring a “rare combination” of scientific excellence and management experience to the role, according to Friedrich Metzger, Co-Founder and CEO of Versameb, who was quoted in the press release.

With Versameb having already achieved important milestones with the VERSagile platform, Dr. Reinhard Ambros, Chairman of the Board of Versameb and former Head of the Novartis Venture Fund, is delighted to see “that the company is attracting excellent talent to perform on our strategic and operational goals and that it is enjoying strong support from its investors”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
TargImmune raises nearly 18 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

TargImmune raises nearly 18 million Swiss francs

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends...

Read More
KetoSwiss launches first product in the USA
Basel Area Business & Innovation, Innovation, Invest

KetoSwiss launches first product in the USA

The Basel-based biotech startup KetoSwiss develops innovative therapies for neurological disorders. Following a successful capital increase, the company now has...

Read More
Basel Area treads unique path
Basel Area Business & Innovation, Innovation, Invest

Basel Area treads unique path

Basel Area is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful...

Read More
Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
RocketVax secures partners for coronavirus vaccine in Basel
Basel Area Business & Innovation, Innovation

RocketVax secures partners for coronavirus vaccine in Basel

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University...

Read More
1 2 3 15

Do you have a question? We'd like to hear from you.